CORCencora
Cencora is one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. 10-K, Item 1
- Employees
- 51,000
- Headquarters
- Conshohocken, PA
- CEO
- Robert P. Mauch
- Next results
- around Feb 3, 2027
Dilution: new shares, stock pay and buybacks
prospectuses (S-3, 424B) of the last three years and the 10-K cash flow From EDGARShares offered
Since Nov 11, 2023: 1 shelf registration.
- Nov 26, 2024 Shelf registration: shares and other securities, amount not fixed S-3ASR
Every offering filing →“We, from time to time, may offer and sell, in one or more offerings, shares of our common stock, shares of our preferred stock, debt securities, depositary shares, warrants, purchase contracts and units.”
S-3ASR, Nov 26, 2024 ↗
Diluted shares: 195.21M in the year to Sep 30, 2025 2025 -2.5%2024 -2.1%2023 -3.1%2022 +1.3%
Change in the diluted weighted average share count from the fiscal year before, stock splits taken out. Bars use one scale for stock pay and buybacks. Prospectuses are read from their cover page; preliminary ones are left out. Cash & buybacks, year by year → · How
FY2025, from the cash flow statement in the 10-K, added up.
Came from
| Operating cash flow | $3.9B |
| Debt raised | $4.5B |
| Shares sold | $29.1M |
Went to
| Capital spending | $668.0M |
| Acquisitions | $4.1B |
| Buybacks | $435.5M |
| Dividends | $437.1M |
| Debt repaid | $1.3B |
| Added to cash | $1.1B |
| Other, net investments bought and sold, other financing and investing lines, and exchange rates |
$399.3M |
Each number is a line of the cash flow statement as the company tagged it. "Other, net" is what those lines do not cover (investments bought and sold, other financing and investing lines, and exchange rates); Tickdelta does not estimate it.
Each CEO's years
The CEO of each fiscal year as named in the proxy's pay versus performance table, and what the 10-Ks show for those years. Facts, not a grade.
Robert P. Mauch
- Operating cash flow
- $3.9B
- Capital spending
- $668.0M
- Acquisitions
- $4.1B
- Buybacks
- $435.5M
- Dividends
- $437.1M
- Stock-based pay
- $148.0M
- Diluted shares since FY2024
- -2.5%
- Revenue since FY2024
- +9%
- Debt since FY2024
- +$2.8B
- CEO pay (reported)
- $18.3M
Steven H. Collis
- Operating cash flow
- $12.8B
- Capital spending
- $1.9B
- Acquisitions
- $7.2B
- Buybacks
- $3.2B
- Dividends
- $1.6B
- Stock-based pay
- $465.6M
- Diluted shares since FY2020
- -2.2%
- Revenue since FY2020
- +55%
- Debt since FY2020
- +$743.6M
- CEO pay (reported)
- $67.6M
| Fiscal year to | Buybacks | Dividends | Stock pay | Shares issued for cash | Diluted shares |
|---|---|---|---|---|---|
| 2025-09-30 | $435.5M | $437.1M | $148.0M | $29.1M | 195.21M |
| 2024-09-30 | $1.5B | $416.2M | $148.0M | $37.8M | 200.28M |
| 2023-09-30 | $1.2B | $398.8M | $124.6M | $61.2M | 204.59M |
| 2022-09-30 | $483.7M | $391.7M | $93.4M | $0 | 211.21M |
| 2021-09-30 | $82.2M | $366.6M | $99.6M | $0 | 208.47M |
From the XBRL of the 10-Ks (cash flow statement and diluted weighted average shares); each year as reported in the latest 10-K that includes it. Concepts: buybacks = PaymentsForRepurchaseOfCommonStock; dividends = PaymentsOfDividendsCommonStock; sbc = ShareBasedCompensation; issuance = ProceedsFromStockOptionsExercised; diluted_shares = WeightedAverageNumberOfDilutedSharesOutstanding.
Work on COR in a spreadsheet:
Excel workbook (a sheet per section, ten years by column, charts, links to the filings) ·
CSV.
For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/COR/export.csv") into a cell.